Business Description

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company founded in 2018 that develops innovative DNA-based treatments for cancer and genetic disorders. Its pipeline features lead candidate FDMT-101 alongside additional programs such as FDMT-102 and FDMT-103, supported by a proprietary delivery platform. Under the leadership of CEO Dr. Michael Hauser and CFO Amanda Clarke, the company has raised over $50 million through strategic collaborations and milestone-based agreements. With several Phase I/II trials on the horizon, 4D Molecular Therapeutics is positioned as a promising emerging competitor in the biotech sphere.

Everything on 4D Molecular Therapeutics Inc.

Revenue (FY2025) $85M
YoY growth +230194.6%
Operating margin -187.2%
Direction Expanding
Gross margin 100.0%
Net margin -164.4%

Leadership & board

View leadership ↗
David Kirn, M.D. — Co-Founder, President, Chief Executive Officer and Director View full profile ↗ John F. Milligan, Ph.D. — Director and Executive Chairman View full profile ↗ Jacob Chacko, M.D., MBA — Director View full profile ↗ Susannah Gray, MBA — Director View full profile ↗ Charles P. Theuer, M.D., Ph.D. — Director View full profile ↗ Nancy Miller-Rich — Director View full profile ↗ Shawn Cline Tomasello, MBA — Director View full profile ↗ Glenn Sblendorio — Director View full profile ↗ Kristian Humer — Chief Financial Officer View full profile ↗ Christopher Simms — Chief Commercial and Business Officer View full profile ↗ Scott Bizily, J.D., Ph.D. — Chief Legal Officer and Corporate Secretary View full profile ↗ Ashoo Gupta — Vice President, Finance and Controller View full profile ↗ Fariborz Kamal, Ph.D. — Former President and Chief Operating Officer; Chief Technical Advisor View full profile ↗ Noriyuki Kasahara, M.D., Ph.D. — Chief Scientific Officer; former Director View full profile ↗ David Schaffer, Ph.D. — Co-Founder and Chief Scientific Advisor; former Director View full profile ↗ Uneek Mehra — Former Chief Financial and Business Officer View full profile ↗ August J. Moretti — Former Chief Financial Officer View full profile ↗ Robert Fishman, M.D. — Former Chief Medical Officer View full profile ↗

Named Competitors

AbbVie Inc.REGENXBIO Inc.Adverum Biotechnologies Inc.Eli Lilly and CompanyEyePoint Inc.Ocular Therapeutix Inc.Kodiak Sciences Inc.Merck & Company Inc.Regeneron Pharmaceuticals Inc.RocheApellis Pharmaceuticals Inc.Astellas Pharma Inc.Annexon Biosciences, Inc.Belite Bio, Inc.Johnson & JohnsonAlnylam Pharmaceuticals, Inc.SanofiStealth BioTherapeutics Inc. +6 more

Recent SEC Filings

2026-06-22 Shareholder vote results View filing ↗
2026-05-07 Reported quarterly results View filing ↗
2026-03-30 Leadership change (directors/officers) View filing ↗
2026-03-18 Reported quarterly results View filing ↗
2026-01-26 Unregistered equity sale View filing ↗
2026-01-07 Reported quarterly results (+1 more) View filing ↗
2025-12-10 Other event View filing ↗
2025-11-17 Leadership change (directors/officers) View filing ↗
2025-11-10 Reported quarterly results View filing ↗
2025-11-07 Other event View filing ↗
2025-11-06 Reported quarterly results (+1 more) View filing ↗
2025-10-31 Entered a material agreement View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.